share_log

8-K: HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

8-K: HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

8-K：HeartSciences提供最新業務並報告2025財年第一季度財務業績
美股SEC公告 ·  09/13 04:20

牛牛AI助理已提取核心訊息

On September 12, 2024, Heart Test Laboratories, Inc., also known as HeartSciences, reported its financial and operational results for the first quarter of fiscal year 2025, which ended on July 31, 2024. The company, which specializes in AI-powered medical technology for heart disease detection, highlighted the progress of its MyoVista wavECGTM device and MyoVista InsightsTM cloud platform. HeartSciences announced a cash and cash equivalents balance of $4.3 million and shareholder’s equity of $5.9 million. Post-quarter, the company secured $1.9 million in non-dilutive financing and extended a $500,000 loan note. The MyoVista Insights Platform is expected to be completed by the end of 2024, with FDA submission targeted for the second half of 2025. The FDA 510(k) submission for the MyoVista wavECGTM device is on track for early 2025. The company also showcased its technology at the United Nations General Assembly Digital Health Symposium and expanded its intellectual property portfolio. Despite these advancements, HeartSciences reported no revenues for Q1 FY2025. The complete financial results have been filed with the U.S. Securities and Exchange Commission.
On September 12, 2024, Heart Test Laboratories, Inc., also known as HeartSciences, reported its financial and operational results for the first quarter of fiscal year 2025, which ended on July 31, 2024. The company, which specializes in AI-powered medical technology for heart disease detection, highlighted the progress of its MyoVista wavECGTM device and MyoVista InsightsTM cloud platform. HeartSciences announced a cash and cash equivalents balance of $4.3 million and shareholder’s equity of $5.9 million. Post-quarter, the company secured $1.9 million in non-dilutive financing and extended a $500,000 loan note. The MyoVista Insights Platform is expected to be completed by the end of 2024, with FDA submission targeted for the second half of 2025. The FDA 510(k) submission for the MyoVista wavECGTM device is on track for early 2025. The company also showcased its technology at the United Nations General Assembly Digital Health Symposium and expanded its intellectual property portfolio. Despite these advancements, HeartSciences reported no revenues for Q1 FY2025. The complete financial results have been filed with the U.S. Securities and Exchange Commission.
2024年9月12日，Heart Test Laboratories, Inc.，也被稱爲HeartSciences，報告了截至2024年7月31日的第一財政季度的財務和運營結果。 該公司專注於用於心臟疾病檢測的人工智能醫療技術，強調了其MyoVista wavECGTm設備和MyoVista InsightsTm雲平台的進展。 HeartSciences宣佈現金及現金等價物餘額爲$430萬，股東權益爲$590萬。季後，該公司獲得了$190萬的非攤薄融資，並延長了一份$500,000的貸款票據。 預計MyoVista Insights平台將在2024年底完成，FDA提交目標定於2025年下半年...展開全部
2024年9月12日，Heart Test Laboratories, Inc.，也被稱爲HeartSciences，報告了截至2024年7月31日的第一財政季度的財務和運營結果。 該公司專注於用於心臟疾病檢測的人工智能醫療技術，強調了其MyoVista wavECGTm設備和MyoVista InsightsTm雲平台的進展。 HeartSciences宣佈現金及現金等價物餘額爲$430萬，股東權益爲$590萬。季後，該公司獲得了$190萬的非攤薄融資，並延長了一份$500,000的貸款票據。 預計MyoVista Insights平台將在2024年底完成，FDA提交目標定於2025年下半年。MyoVista wavECGTm設備的FDA 510(k)提交計劃在2025年初完成。該公司還在聯合國大會數字健康研討會上展示了其技術，並擴展了其知識產權組合。 儘管取得了這些進展，HeartSciences報告Q1 FY2025沒有任何收入。 完整的財務結果已向美國證券交易委員會提交。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間